News & Events

Latest Blog Posts & Events

Delivering Palliative Care via Telehealth Meets Patients’ Needs
Care delivered virtually was just as effective at improving patients’ quality of life as delivering care in person.
Program Connects AYAs to Quality Cancer Care
A UNC program for adolescents and young adults with cancer expands access to recommended treatment and services.
Will Ponsegromab Be a Game Changer for Cancer Cachexia?
In a clinical trial, the drug helped people with the wasting syndrome gain weight and muscle.

Latest Press Releases

NIH-funded scientists uncover clues to precancer and tumor biology
- October 30, 2024
New studies released by NCI’s Human Tumor Atlas Network explore the role of the tumor microenvironment and the immune system in promoting the spread of cancer and its resistance to treatment. The studies appear across several Nature journals.
NIH clinical trial will test precision medicine treatments for myeloid cancers
- October 23, 2024
NCI has launched myeloMATCH, a precision medicine treatment trial that will test treatment combinations targeting specific genetic changes in people with acute myeloid leukemia and myelodysplastic syndromes.
New cancer diagnoses did not rebound as expected following pandemic
- September 24, 2024
While new cancer diagnoses largely returned to pre-pandemic levels in 2021, they don’t account for the missed diagnoses in early 2020 that resulted from disruptions in cancer screening and other medical care.
NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
- September 16, 2024
A new study suggests, for men with West African genetic ancestry, living in a disadvantaged neighborhood was associated with a higher risk of prostate cancer. The researchers posit that chronic stress—such as from racial profiling, housing discrimination, and exposure to violence—may be a possible driver.
Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
- September 16, 2024
An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.